生物活性

• 描述Perindopril erbumine is a potent ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease. Target: ACE Perindopril is a long-acting ACE inhibitor^[3]. It is indicated for the treatment of essential hypertension either alone or in combination with other antihypertensives, especially thiazide diuretics^[4]. Perindopril is effective and safe for blood pressure control with a dose-dependent effect. Perindopril in combination with amlodipine significantly reduced total and cardiovascular mortality as compared to atenolol/diuretic in large-scale clinical trials of hypertensive patients^[5]. Perindopril 4 to 8 mg once daily significantly reduces supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline values in hypertensive patients. Perindopril 4 to 8 mg once daily significantly decreased carotid-femoral aortic pulse wave velocity (PWV), improved arterial compliance, reduced left ventricular mass index and, in patients with recent cerebral ischaemia and/or stroke, preserved cerebral blood flow despite significantly reducing SBP and DBP^[6].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02817360	Heart Diseases ... more >> Diabetes Mellitus, Type 2 Collapse <<	Phase 4	Recruiting	February 2021	Austria ... more >> Internistische Ordination Recruiting Mödling, Niederösterreich, Austria, 2340 Contact: Christian Feinböck, MD    +43 2236 869 142    office@dr-feinboeck.at    Contact: Christiane Feinböck    +43 2236 869 142    office@dr-feinboeck.at    Sub-Investigator: Egbert Seyfried, MD          Principal Investigator: Christian Feinböck, MD          Klinischen Abteilung für Endokrinologie und Diabetologie MU Graz Recruiting Graz, Steiermark, Austria, 8036 Contact: Harald Sourij    +43-316-385-80363    ha.sourij@medunigraz.at    Contact: Michael Zink    +43-680-128-5120    m.zink@medunigraz.at    Sub-Investigator: Julia Mader, MD Prof          Sub-Investigator: Eva Novak, MD          Sub-Investigator: Caren Sourij, MD          Konventhospital der Barmherzigen Brüder Abteilung für Innere Medizin Recruiting Linz, Upper Austria, Austria, 4021 Contact: Martin Clodi, Prof.Dr.       martin.clodi@bblinz.at    Principal Investigator: Martin Clodi, Prof.Dr.          Sub-Investigator: Michael Resl, Dr.          Krankenanstalt Rudolfstiftung, 1. Medizinische Abteilung Recruiting Vienna, Austria, 1030 Contact: Bernhard Ludvik, Prof.Dr.    +43 1 711 65 ext 2107    bernhard.ludvik@wienkav.at    Principal Investigator: Bernhard Ludvik, Prof.Dr.          Sub-Investigator: Eva-Christina Krzizek, Dr.          Sub-Investigator: Johanna Brix, Dr.          Sub-Investigator: Astrid Feder, Dr.          Sub-Investigator: Florian Hoellerl, Dr.          Medical University of Vienna Univ.Clinic for Internal Medicine II Department of Cardiology Recruiting Vienna, Austria, 1090 Contact: Martin Huelsmann, Doz.Dr.    +43 1 40400 ext 46140    martin.huelsmann@meduniwien.ac.at    Principal Investigator: Martin Huelsmann, Doz.Dr.          Sub-Investigator: Raphael Wurm, Dr.          Univ. Klinik für Innere Medizin III Med. Uni Wien Recruiting Vienna, Austria, 1090 Contact: Anton Luger, Prof.Dr.    00 43 1 40400 ext 43100    anton.luger@meduniwien.ac.at    Principal Investigator: Anton Luger, Prof.Dr.          Sub-Investigator: Michael Krebs, Prof.Dr.          Universitätsklinik für Augenheilkunde und Optometrie Medizinische Universität Wien Recruiting Vienna, Austria, 1090 Contact: Sonja Prager, Dr.    +43 1 40400 ext 79470    sonja.prager@meduniwien.ac.at    Principal Investigator: Sonja Prager, Dr.          Sub-Investigator: Julia Hafner, Dr.          Diabetes & Stoffwechselambulanz Gesundheitszentrum Wien Süd Recruiting Vienna, Austria, 1100 Contact: Helmut Brath, OA Dr.    +43 1 60122 ext 4264    helmut.brath@wgkk.at    Principal Investigator: Helmut Brath, OA Dr.          3. Med. Abtlg., KH Hietzing mit Neurologischem Zentrum Rosenhügel Recruiting Vienna, Austria, 1130 Contact: Rudolf Prager, Prof.Dr.    +43 1 80110 ext 2351    rudolf.prager@wienkav.at    Principal Investigator: Rudolf Prager, Prof.Dr.          Sub-Investigator: Slobodan Peric, Dr.          Zentrum für Klinische Studien Recruiting Wien, Austria, 1060 Contact: Ursula Hanusch, MD    +43 1 266 21 91    dr.hanusch@dieinternistin.com    Contact: Michaela Mauritz    +43 1 266 21 91    office@dieinternistin.com    Sub-Investigator: Marita Spak, MD          Netherlands Maastricht University Medical Center; Dep. Cardiology Recruiting Maastricht, Netherlands, 6202 Contact: Hans-Peter Brunner-La Rocca, MD Prof    +31 43-3877097    hp.brunnerlarocca@mumc.nl    Contact: Mireille Spanjers    +31 43-3877099    m.spanjers@mumc.nl    Sub-Investigator: Nick Marks, MD          Sub-Investigator: Wouter Robaeys, MD          New Zealand Christchurch Heart Institute Recruiting Christchurch, New Zealand, 8140 Contact: Richard Troughton, MD Prof    +64 3 364 1063    Richard.Troughton@cdhb.health.nz    Contact: Lorraine Skelton    +64 3 364 1063    lorraine.skelton@cdhb@health.nz    Principal Investigator: Richard Troughton, MD Prof Collapse <<
  NCT01715584	Hypertension	Phase 4	Recruiting	December 31, 2019	Canada, Ontario ... more >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD    519 685 8500 ext 58525    Craig.Railton@lhsc.on.ca    Principal Investigator: Craig J Railton, MD, PhD          Sub-Investigator: Jonathan Fairbairn, BSc          Sub-Investigator: George Nicoloau, MD          Sub-Investigator: Robert Gros, PhD          Sub-Investigator: Jason Franklin, MD          Sub-Investigator: John Yoo, MD          Sub-Investigator: Kevin Fung, MD          Sub-Investigator: Anthony Nichols, MD          Sub-Investigator: Danielle McNeil, MD Collapse <<
  NCT01669434	-	-	Completed	-	-

• 更多
• 参考文献

• [1] Zou K, Maeda T, et al. Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem. 2009 Nov 13;284(46):31914-20.

  [2] Ceconi C, Francolini G, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6.

  [3] áclavík J. Perindopril v léčbě hypertenze a kardiovaskulárních chorob: evoluce pokračuje orodisperzní formou [Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form]. Vnitr Lek. 2013 Apr;59(4):290-4. Czech

  [4] O'Loughlin DC, Chu VL, Singh D. Perindopril. Heart Dis. 2000 Nov-Dec;2(6):446-55

  [5] Ghiadoni L. Perindopril for the treatment of hypertension. Expert Opin Pharmacother. 2011 Jul;12(10):1633-42

  [6] Hurst M, Jarvis B. Perindopril: an updated review of its use in hypertension. Drugs. 2001;61(6):867-96

• 更多

• Collapse